# Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes

> **NCT07173712** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Yanbing Li** · enrollment: 324 (estimated)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** CSII
- **DRUG:** Insulin glargine /lixisenatide Fixed Ratio Combination
- **DRUG:** Insulin Degludec and Insulin Aspart Injection
- **DRUG:** Insulin Glargine (HOE901 - U300)
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT07173712
- **Lead sponsor:** Yanbing Li
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-15
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 324 (ESTIMATED)
- **Last updated:** 2026-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07173712

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07173712, "Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT07173712. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*